Cytokinetics, Incorporated (CYTK) Profit Margins
Over the twelve months to 2026-06-30, Cytokinetics, Incorporated (CYTK) had operating margin -1046.1%, net margin -1321.1%, free cash flow margin -858.2%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CYTKCytokinetics, IncorporatedFollow CYTK — free
—
Price chart with a free account
- Market cap
- 8.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 70.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating margin | -1199.1% | -535.2% | -110.6% | -31.4% | -130.5% | 17.6% | -848.3% | -282.3% | -368.0% | -168.3% | -264.5% | -342.8% | -6589.7% | -2902.7% | -695.4% | -1046.1% | |
| Net margin | -1196.5% | -534.1% | -110.0% | -31.2% | -130.9% | 15.5% | -955.9% | -337.4% | -452.9% | -228.0% | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% | -1321.1% | |
| FCF margin | -1150.9% | -444.0% | -27.0% | -97.9% | 15.1% | 33.3% | -782.7% | -324.1% | -348.1% | -3.8% | -271.8% | -328.6% | -5521.2% | -2164.1% | -607.5% | -858.2% |
USD billions · SEC XBRL
Cytokinetics, Incorporated — questions
- What is Cytokinetics, Incorporated's operating margin?
- -1046.1% over the twelve months to 2026-06-30.
- What is Cytokinetics, Incorporated's net profit margin?
- -1321.1% over the twelve months to 2026-06-30.
Every figure on this page comes from Cytokinetics, Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.